Plus TherapeuticsPSTV
PSTV
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 21
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
60% more funds holding
Funds holding: 10 [Q4 2024] → 16 (+6) [Q1 2025]
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
8.19% less ownership
Funds ownership: 11.49% [Q4 2024] → 3.3% (-8.19%) [Q1 2025]
53% less capital invested
Capital invested by funds: $780K [Q4 2024] → $369K (-$411K) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
734%
upside
Avg. target
$10.83
2,912%
upside
High target
$21
5,599%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Sean Lee | 734%upside $3 | Buy Maintained | 27 Jun 2025 |
D. Boral Capital Jason Kolbert | 2,402%upside $9 | Hold Maintained | 25 Jun 2025 |
Ascendiant Capital Edward Woo | 5,599%upside $21 | Buy Maintained | 5 Jun 2025 |
Financial journalist opinion
Based on 8 articles about PSTV published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases
Neutral
GlobeNewsWire
3 days ago
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Substantial clinical need expected to facilitate rapid overall trial enrollment Substantial clinical need expected to facilitate rapid overall trial enrollment
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from the Cancer Prevention & Research Institute of Texas HOUSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the initiation of the ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM). The dose optimization trial follows encouraging results from the Company's single-dose escalation trial and is designed to evaluate multiple-dose regimens of REYOBIQ administered at defined intervals via intraventricular catheter (Ommaya reservoir).
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients suspected of having central nervous system cancer metastases (CNS Mets).
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details.
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application (No. 168178) for REYOBIQTM (Rhenium Re186 Obisbemeda) for the treatment of pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma.
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC
Positive
Zacks Investment Research
3 weeks ago
Plus (PSTV) Upgraded to Buy: Here's Why
Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Negative
Zacks Investment Research
1 month ago
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2025, and provides an overview of recent and upcoming business highlights. “We improved our cash position in the first quarter as a result of both a financing and grant support,” said Marc H.
Charts implemented using Lightweight Charts™